AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04843579
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given as 500 mg oral capsule
Trial: NCT05163223
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q3W, 3 cycles, Plus a booster at 24 weeks post the third vaccination, Intradermal injection
Trial: NCT05163223
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On days 1-14 (Q3W), BID ; Oral administration,
Trial: NCT04829435
Drug: ALLN-346
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration; It is a proprietary enzyme designed to degrade urate in the intestinal tract
Trial: NCT04829435
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
Trial: NCT05274204
Drug: CA102N
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05408247
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT00899587
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05445856
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl is administered as a single intravenous dose after induction of anesthesia and prior to initiation of surgery
Trial: NCT01351168
Drug: Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CD/LD 25/100, 2 tablets test dose based on subject's current CD/LD dosing; single randomized testing day
Trial: NCT04711603
Drug: MR13A9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration
Trial: NCT04711603
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration
Trial: NCT05106205
Drug: DA-5213-R 10mg
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose administration (one tablet once a day)
Trial: NCT04789577
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received two doses of Placebo by intramuscular injection in the non-dominant arm.
Trial: NCT06169072
Drug: Superparamagnetic Iron Oxide
RxNorm normalized name: Superparamagnetic iron oxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superparamagnetic iron oxide (SPIO) consists of an iron oxide nanoparticle core and a hydrophilic coating to make it biocompatible and colloidal stable in a suspension. In this study injected intradermally in an ultra-low dose
Trial: NCT05451667
Drug: YJ001 for Spray Use
RxNorm normalized name: Antibiotics for systemic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YJ001 (active ingredient)
Trial: NCT05451667
Drug: Placebo of YJ001 for Spray Use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxypropyl Methylcellulose
Trial: NCT05304455
Drug: subcutaneous Low Molecular Weight Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.
Trial: NCT05145543
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 NaCl % (Saline) (5 ml) will be applied
Trial: NCT05145543
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fentanyl plus 0.25 % levobupivacaine (5 ml) will be applied.
Trial: NCT06383650
Drug: Acetylsalicylic Acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will undergo CT imaging with the use of contrast for diagnosis of BCVI. Patients will be monitored for feasibility outcomes, as well as the development of stroke and bleeding complications.
Trial: NCT00002439
Drug: Alitretinoin
RxNorm normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05926869
Drug: Clindamycin and Dapsone gel for 03 months
RxNorm normalized name: dapsone Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin is a topical antibiotic which has been widely used in treatment of acne for many decades. Topical Dapsone 5% gel contains sulfone and has an advanced solvent micro particulate delivery system that enables penetration of stratum corneum . It is a new topical drug used in the treatment of Moderate Acne Vulgaris. It has antibacterial as well as anti inflammatory effects
Trial: NCT05262751
Drug: Ofev®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofev®
Trial: NCT05631704
Drug: VH4524184
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VH4524184 will be administered.
Trial: NCT05631704
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered.
Trial: NCT05941247
Drug: Hemay005 60 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The eligible healthy adult participants will enter Single-dose Administration Period, receiving a single administration of Hemay005 tablets orally at a dose of 60 mg on Day 1 morning under fasted condition.~On Day 3, those participants will receive Hemay005 tablets at dose of 60 mg for 7 consecutive days, which will be administrated twice daily (BID) during Day 3 to Day 8 and only in the morning on Day 9.
Trial: NCT06016218
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparing Simvastatin powder with PRF to Bone Powder with PRF on Peri-implant Bone
Trial: NCT06379542
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets/day for 7-14 days
Trial: NCT05299255
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the placebo as control group.
Trial: NCT05391360
Drug: Freethiadine placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive either a single dose of Freethiadine on Day 1 only (SAD HV), twice daily dosing of Freethiadine starting on Day 1 through Day 10 (MAD HV)
Trial: NCT04996433
Drug: algorithm-based study medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive an optimized, algorithm-based antidepressant medication following the current S3-Guidelines on Unipolar Depression. In case of nonresponse:~* 1st line dose escalation (if appropriate)~* 2nd line lithium augmentation~* 3rd line augmentation with 2nd generation antipsychotics or evidence-based combinations of antidepressants~* 4th line change of antidepressant.
Trial: NCT04964349
Drug: Corticosteroids Acting Locally
RxNorm normalized name: Corticosteroids acting locally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical application of jessener solution
Trial: NCT05675813
Drug: standard CHOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the 6 cycles.
Trial: NCT06184035
Drug: [177Lu]Lu-SN201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT05333874
Drug: Neoadjuvant chemotherapy administered before surgical extraction of a tumor
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SignateraTM is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer. The Signatera methodology is personalized and tumor-informed, providing each individual with a customized blood test tailored to fit the unique signature of clonal mutations found in that individual's tumor tissue. This maximizes accuracy for detecting the presence or absence of disease in a blood sample, even at levels down to a single tumor molecule in a tube of blood. Signatera is intended to detect and quantify how much cancer is left in the body, to improve prognosis and help optimize treatment decisions, based on the tissue-informed testing of mutations.
Trial: NCT05072522
Drug: SKLB1028
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKLB1028 capsules, oral, once daily in continuous 28-day cycles
Trial: NCT06330935
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 patients will be randomized this arm C
Trial: NCT05465590
Drug: MB1707
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MB1707 is a CXCR4 antagonist peptide-conjugated paclitaxel.~MB1707, paclitaxel (PTX) conjugated CXC chemokine receptor 4 (CXCR4) peptide antagonist, a peptide-drug conjugate (PDC), for the treatment of cancer. MB1707 is a potent CXCR4 antagonist which inhibits tumor growth and metastasis by blocking the stromal cell derived factor 1 (SDF-1, a.k.a. CXCL12)/CXCR4 signaling pathway. MB1707 contains a conjugated drug, paclitaxel. By specific binding to CXCR4 overexpressed by the tumor cells, MB1707 has a built-in targeted delivery mechanism.
Trial: NCT05092074
Drug: Vosevi 400/100/100 Oral Tablet
RxNorm normalized name: Vosevi 400/100/100 Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX, Vosevi) 400/100/100 oral tablet: 1 table per os per day for 12 weeks
Trial: NCT06031636
Drug: Oncolytic Adenovirus H101
RxNorm normalized name: adenovirus, type 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The oncolytic virus(H101) is administered by intratumoral injection or intrapleural injection on days 1-3 of the first medication cycle. PD-1 inhibitor is administered on days 4 or 5, with one infusion per cycle. The treatment regimen consists of 2-4 cycles
Trial: NCT06031636
Drug: Programmed death receptor-1 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The oncolytic virus(H101) is administered by intratumoral injection or intrapleural injection on days 1-3 of the first medication cycle. PD-1 inhibitor is administered on days 4 or 5, with one infusion per cycle. The treatment regimen consists of 2-4 cycles
Trial: NCT06115902
Drug: TQB2102 for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)
Trial: NCT06492447
Drug: Against HER 2-ADC Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast cancer subjects receiving anti-HER2-ADC drugs were treated with a 3-week treatment cycle lasting 6 cycles. Serum of patients before and after treatment was collected, and the changes of serum HER2 level before chemotherapy and after 2, 4 and 6 cycles of chemotherapy were dynamically monitored, and the relationship between HER2 level and the therapeutic effect of different targeted drugs was analyzed.
Trial: NCT06437951
Drug: Fexuprazan Injection
RxNorm normalized name: fexuprazan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20/40/80 mg
Trial: NCT06437951
Drug: Fexuprazan tablet
RxNorm normalized name: fexuprazan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg
Trial: NCT05613777
Drug: Microgynon®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ethinylestradiol (EE) and levonorgestrel (LNG)
Trial: NCT04693039
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.
Trial: NCT00329212
Drug: San Huang Xie Jin Tang
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05337553
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DB Phase: matching placebo 35 mg/50 mg weekly subcutaneous injection
Trial: NCT05003492
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infected patients will receive the standard therapy for COVID-19 for 14 days
Trial: NCT04853446
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two identically appearing, opaque capsules will be administered: two capsules containing placebo.
Trial: NCT05970705
Drug: Trifluridine/Tipiracil
RxNorm normalized name: TRIFLURIDINE/TIPIRACIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: this chemotherapeutic drug is also one of the standard third-line treatment options for patients with metastatic colorectal cancer
Trial: NCT04341155
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in placebo arms will receive 20 mL normal saline intravenously for 7 days
Trial: NCT05922982
Drug: norepinephrine weaning protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAP-based (MAP \> 65 mmHg) norepinephrine weaning protocol
Trial: NCT05922982
Drug: norepinephrine weaning protocol and guided by the HPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAP-based (MAP \> 65 mmHg) norepinephrine weaning protocol and guided by the HPI (HPI\<80) delivered by the Acumen IQ medical device.
Trial: NCT01433393
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00417014
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04983979
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched placebo given titrated according to potassium at a dose to 5 or 10g
Trial: NCT00000611
Drug: progestins
RxNorm normalized name: PROGESTINS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000611
Drug: calcium
RxNorm normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05969522
Drug: GlucoCorticoid
RxNorm normalized name: Glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The high-risk group: methylprednisolone intravenous 15-30mg/kg/d (Max.500mg/d)\*3 days , with 2 courses, interval 5-7 days;Oral prednisone acetate 1.5-2mg/kg/d (Max. 60mg/d) during methylprednisolone impact interval and later stage, with the first reduction after 2-4 weeks. The dose was reduced once every 3 weeks in the first 3 months, and once every 4 weeks in the next 3 months, with a reduction of 5-10mg/ day each time; Rituximab：375 mg/m2/ time, once a week for 4 times;Intravenous cyclophosphamide 7.5-10mg/kg.d\*2 days(Max.500mg/d), once every 4 weeks, twice in total, at the 8th and 12th week.The medium-low risk group: methylprednisolone was the same dose as before, but only with 1 course, then followed by oral prednisone acetate 1.5-2mg/kg/d (Max. 60mg/d), divided into three times for 3 weeks, and then changed to morning daily; The dose was reduced as the high-risk group ;Rituximab was the same dose as before.
Trial: NCT05942820
Drug: BWC0977
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAD Cohorts: Double-blind dosing will occur. Six participants will receive single doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. MAD Cohorts: Double blind dosing will occur. Six participants in each cohort will receive multiple doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Dosing frequency to be confirmed based on safety, tolerability and PK data from SAD cohorts. Daily dosing will continue for a total of 10 consecutive days.
Trial: NCT05942820
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAD Cohorts: Two participants in each cohort will receive a matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.~Other Names:~• Compounded solution minus BWC0977
Trial: NCT04785118
Drug: Hyoscine N Butylbromide
RxNorm normalized name: Hyoscine N butylbromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive IV hyoscine butyl-bromide 20 mg in 2 ml, just before spinal anaesthesia.
Trial: NCT05474989
Drug: Active placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose LSD
Trial: NCT04736589
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy drugs are not limited in this trial, please refer to their instructions for specific usage.
Trial: NCT06321250
Drug: JMKX003948
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive JMKX003948 tablets until disease progression
Trial: NCT06526377
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06273813
Drug: Ketorolac Tromethamine 15 MG/ML
RxNorm normalized name: ketorolac tromethamine 15 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous administration of Ketorolac Tromethamine injection in Cohort 1 on day 1
Trial: NCT06435949
Drug: Fentanyl (as Citrate)
RxNorm normalized name: fentanyl (as citrate)
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous anesthesia with propofol with fentanyl (group Fentanyl) and propofol with oxycodone (group Oxycodone)
Trial: NCT04724720
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care treatment plus placebo
Trial: NCT05351320
Drug: WX-0593 Tablets
RxNorm normalized name: WX-554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WX-0593 60 mg, tablets, orally, once daily for 7 days, followed by WX-0593 180 mg, tablets, orally, once daily
Trial: NCT05351320
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based chemotherapy
Trial: NCT04965675
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to eptinezumab will be administered per schedule specified in the arm.
Trial: NCT06285617
Drug: 1-week predisone+1-week celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 and 10 mg prednisone in the morning and afternoon, respectively, daily for 1 week; in the second week, these participants received 400 mg celecoxib (a type of nonsteroidal anti-inflammatory drug) on day 1 and 200 mg twice daily for the remaining 6 days until celecoxib withdrawal.
Trial: NCT06285617
Drug: 6-weeks predisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 and 10 mg prednisone in the morning and afternoon, respectively, daily in the first week, and then reduced by 5 mg/week from the second week until withdrawal in the sixth week.
Trial: NCT05821556
Drug: Simvastatin 20mg
RxNorm normalized name: SIMVASTATIN 20MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected.
Trial: NCT05821556
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected.
Trial: NCT05222425
Drug: Xagrotin
RxNorm normalized name: Naprotin KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A herbal compound
Trial: NCT04707664
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients in the control arm will receive an equivalent volume of inhaled placebo diluent administered via a vibrating mesh nebulizer once daily for 5 days.
Trial: NCT05266651
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets for one month duration
Trial: NCT05216224
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet manufactured to match ATI-450 in appearance
Trial: NCT05764239
Drug: SYNB1934v1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYNB1934v1 consisted of powder for oral suspension packaged in sachets. During dose preparation, the powder was resuspended in water or apple juice prior to administration.
Trial: NCT05764239
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was manufactured using an inactive powder that was color matched to the SYNB1934v1 drug product. In order to maintain study blinding during the RWP, placebo was packaged, labeled, stored, and administered in an identical manner to SYNB1934v1.
Trial: NCT06221072
Drug: JMT103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg by subcutaneous injection every 4 weeks